RU2740059C2 - Капсулы с растворимым эстрадиолом для интравагинального введения - Google Patents

Капсулы с растворимым эстрадиолом для интравагинального введения Download PDF

Info

Publication number
RU2740059C2
RU2740059C2 RU2015100531A RU2015100531A RU2740059C2 RU 2740059 C2 RU2740059 C2 RU 2740059C2 RU 2015100531 A RU2015100531 A RU 2015100531A RU 2015100531 A RU2015100531 A RU 2015100531A RU 2740059 C2 RU2740059 C2 RU 2740059C2
Authority
RU
Russia
Prior art keywords
composition
estradiol
pharmaceutical composition
estrogen
fatty acid
Prior art date
Application number
RU2015100531A
Other languages
English (en)
Russian (ru)
Other versions
RU2015100531A (ru
Inventor
Брайан А. БЕРНИК
Джулия М. АМАДИО
Питер Х.Р. ПЕРСИКАНЕР
Торстейнн ТОРСТЕЙНССОН
Дженис Луиза КАКЕЙС
Original Assignee
Терапьютиксмд, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49769313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2740059(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/684,002 external-priority patent/US8633178B2/en
Priority claimed from PCT/US2013/023309 external-priority patent/WO2013112947A1/en
Priority claimed from US13/843,428 external-priority patent/US9301920B2/en
Application filed by Терапьютиксмд, Инк. filed Critical Терапьютиксмд, Инк.
Publication of RU2015100531A publication Critical patent/RU2015100531A/ru
Application granted granted Critical
Publication of RU2740059C2 publication Critical patent/RU2740059C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
RU2015100531A 2012-06-18 2013-06-18 Капсулы с растворимым эстрадиолом для интравагинального введения RU2740059C2 (ru)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201261661302P 2012-06-18 2012-06-18
US61/661,302 2012-06-18
US201261662265P 2012-06-20 2012-06-20
US61/662,265 2012-06-20
US13/684,002 US8633178B2 (en) 2011-11-23 2012-11-21 Natural combination hormone replacement formulations and therapies
US13/684,002 2012-11-21
US201261745313P 2012-12-21 2012-12-21
US61/745,313 2012-12-21
PCT/US2013/023309 WO2013112947A1 (en) 2012-01-26 2013-01-25 Transdermal hormone replacement therapies
USPCT/US2013/023309 2013-01-25
US13/843,428 US9301920B2 (en) 2012-06-18 2013-03-15 Natural combination hormone replacement formulations and therapies
US13/843,428 2013-03-15
PCT/US2013/046443 WO2013192249A1 (en) 2012-06-18 2013-06-18 Soluble estradiol capsule for vaginal insertion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2020140867A Division RU2020140867A (ru) 2012-06-18 2013-06-18 Капсулы с растворимым эстрадиолом для интравагинального введения

Publications (2)

Publication Number Publication Date
RU2015100531A RU2015100531A (ru) 2016-08-10
RU2740059C2 true RU2740059C2 (ru) 2020-12-31

Family

ID=49769313

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015100531A RU2740059C2 (ru) 2012-06-18 2013-06-18 Капсулы с растворимым эстрадиолом для интравагинального введения
RU2020140867A RU2020140867A (ru) 2012-06-18 2013-06-18 Капсулы с растворимым эстрадиолом для интравагинального введения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2020140867A RU2020140867A (ru) 2012-06-18 2013-06-18 Капсулы с растворимым эстрадиолом для интравагинального введения

Country Status (13)

Country Link
EP (2) EP3909586A1 (enExample)
JP (3) JP6397402B2 (enExample)
AU (3) AU2013277234B2 (enExample)
BR (1) BR112014031914B1 (enExample)
CA (1) CA2876968C (enExample)
ES (1) ES2869250T3 (enExample)
HR (1) HRP20210861T1 (enExample)
HU (1) HUE055275T2 (enExample)
IL (1) IL236359B (enExample)
MX (2) MX393195B (enExample)
PL (1) PL2861073T3 (enExample)
RU (2) RU2740059C2 (enExample)
WO (1) WO2013192249A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2018538290A (ja) * 2015-12-07 2018-12-27 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 膣挿入エストラジオール医薬組成物および方法
WO2017105512A1 (en) * 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US20220378697A1 (en) * 2019-10-31 2022-12-01 R.P. Scherer Technologies, Llc Suppository capsule

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2155582C2 (ru) * 1994-12-22 2000-09-10 Лаборатуар Иннотера Дозированная галенова композиция для вагинального применения в качестве местного контрацептивного средства и/или для борьбы с заболеваниями, передающимися половым путем, и/или вич
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20070036843A1 (en) * 2005-01-28 2007-02-15 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
US20090136574A1 (en) * 2006-04-19 2009-05-28 Galderma S.A. Compositions comprising at least one aqueous phase and at least one fatty phase which comprises avermectin compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US694192A (en) * 1901-04-20 1902-02-25 William C Rastetter Vehicle-wheel.
IT1090703B (it) * 1976-12-03 1985-06-26 Scherer Ltd R P Perfezionamento nelle composizioni utili quali veicolo per farmaci
US4384096A (en) * 1979-08-27 1983-05-17 The Dow Chemical Company Liquid emulsion polymers useful as pH responsive thickeners for aqueous systems
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
FR2739558B1 (fr) * 1995-10-05 1997-11-28 Innothera Lab Sa Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US6018033A (en) 1997-05-13 2000-01-25 Purdue Research Foundation Hydrophilic, hydrophobic, and thermoreversible saccharide gels and forms, and methods for producing same
NZ330726A (en) * 1998-06-18 2000-10-27 Dec Res Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20060134188A1 (en) * 2004-12-20 2006-06-22 Hans-Peter Podhaisky Transdermal pharmaceutical preparation with a progesterone A-specific ligand (PRASL) as active ingredient
EP1971325A2 (en) * 2005-12-27 2008-09-24 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
WO2007103294A2 (en) * 2006-03-07 2007-09-13 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
US20070287789A1 (en) * 2006-06-07 2007-12-13 Stephen Ray Jones Bleed-resistant colored microparticles
CN101474167A (zh) * 2009-01-23 2009-07-08 西安德天药业股份有限公司 雌二醇阴道用胶囊的制备方法
US9301920B2 (en) * 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) * 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2155582C2 (ru) * 1994-12-22 2000-09-10 Лаборатуар Иннотера Дозированная галенова композиция для вагинального применения в качестве местного контрацептивного средства и/или для борьбы с заболеваниями, передающимися половым путем, и/или вич
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20070036843A1 (en) * 2005-01-28 2007-02-15 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
US20090136574A1 (en) * 2006-04-19 2009-05-28 Galderma S.A. Compositions comprising at least one aqueous phase and at least one fatty phase which comprises avermectin compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Simon J. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet // Obstet Gynecol. 2008 Nov;112(5):1053-60. *

Also Published As

Publication number Publication date
JP2020100642A (ja) 2020-07-02
RU2020140867A (ru) 2021-06-10
AU2019204653A1 (en) 2019-07-18
AU2019204653B2 (en) 2021-07-08
MX2014015899A (es) 2015-03-03
JP6682127B2 (ja) 2020-04-15
AU2017208300A1 (en) 2017-08-17
BR112014031914B1 (pt) 2021-12-14
CA2876968C (en) 2022-09-13
AU2013277234A1 (en) 2015-01-22
JP2015519405A (ja) 2015-07-09
BR112014031914A2 (pt) 2017-06-27
JP6397402B2 (ja) 2018-09-26
CA2876968A1 (en) 2013-12-27
MX358435B (es) 2018-08-03
EP2861073B1 (en) 2021-04-14
HRP20210861T1 (hr) 2021-09-17
EP2861073A1 (en) 2015-04-22
RU2015100531A (ru) 2016-08-10
WO2013192249A1 (en) 2013-12-27
IL236359B (en) 2020-11-30
PL2861073T3 (pl) 2021-09-27
HUE055275T2 (hu) 2021-11-29
EP3909586A1 (en) 2021-11-17
JP2018199711A (ja) 2018-12-20
AU2013277234B2 (en) 2017-04-27
IL236359A0 (en) 2015-02-26
EP2861073A4 (en) 2015-12-23
MX393195B (es) 2025-03-24
ES2869250T3 (es) 2021-10-25

Similar Documents

Publication Publication Date Title
US11123283B2 (en) Soluble estradiol capsule for vaginal insertion
RU2740059C2 (ru) Капсулы с растворимым эстрадиолом для интравагинального введения
US10835487B2 (en) Vaginal inserted estradiol pharmaceutical compositions and methods
US20150359737A1 (en) Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) Vaginal inserted estradiol pharmaceutical compositions and methods
CA2926342A1 (en) Vaginal inserted estradiol pharmaceutical compositons and methods
KR102163369B1 (ko) 질 삽입용 가용성 에스트라디올 캡슐
US20250360079A1 (en) Vaginal inserted estradiol pharmaceutical compositions and methods
KR102488424B1 (ko) 질내 삽입형 에스트라다이올 약제학적 조성물 및 방법